
    
      The participants will receive 2 cycles of pemetrexed and cisplatin. If the participants
      achieve complete response, partial response or stable disease as defined by Response
      Evaluation Criteria in Solid Tumors (RECIST) guidelines, have â‰¤35% of the total calculated
      lung volume receive more than 20 Gy (V20) according to the 3-dimensional (3-D) radiotherapy
      planning Dose Volume Histograms, have an Eastern Cooperative Oncology Group (ECOG)
      performance status of 0 or 1, have no residual neurological toxicity > Grade 2 according to
      Common Terminology Criteria for Adverse Events (CTCAE), they will receive 2 additional cycles
      of pemetrexed and cisplatin, combined with radiotherapy. The combination of radiotherapy will
      begin 22 to 36 days after completion of the second infusion of induction therapy with
      pemetrexed-cisplatin.
    
  